The restoration
of balance

Pipeline

Therapeutic Focus Discovery Pre-clinical Phase 1 Phase 1b/2 Phase 2 Phase 3
Resokine Pathway / Muscle
Resolaris™ for Adult FSHD
67%
Resolaris™ for Early Onset FHSD
67%
Resolaris™ for Adult LGMD2B
67%
Resokine Pathway / Lung
Stalaris for Rare Lung Disease
35%
Physiocrine R&D
 
16%

Therapeutic Focus Phase
Resokine Pathway / Muscle
Resolaris for Adult FSHD Phase 1b/2
Resolaris for Early Onset FHSD Phase 1b/2
Resolaris for Adult LGMD2B Phase 1b/2
Resokine Pathway / Lung
iMod.Fc for Rare Lung Disease Pre-clinical
Physiocrine R&D
  Discovery

We intend to leverage our unique understanding of Physiocrines and our broad intellectual property portfolio, which we believe covers this entire class of potential protein therapeutics, to build a pipeline of product candidates that we expect to develop and commercialize independently for the treatment of various rare diseases.

© 2007 - 2017   aTyr Pharma.   Legal   Privacy Policy